# Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)

Study · id `cardio:ct-nct06045858` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06045858](<https://clinicaltrials.gov/study/NCT06045858>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06045858

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 178 participants.

## Technical summary

Registry record NCT06045858. Randomized; single masking; primary purpose treatment. Start 2024-10-30 (anticipated); primary completion 2027-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 178 participants (planned count; ClinicalTrials.gov record NCT06045858, source copy `cardio:ctgov-nct06045858-2024-08-09`, retrieved 2026-10-26)
- Planned start: 2024-10-30 (anticipated) (ClinicalTrials.gov record NCT06045858, source copy `cardio:ctgov-nct06045858-2024-08-09`, retrieved 2026-10-26)
- Primary completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT06045858, source copy `cardio:ctgov-nct06045858-2024-08-09`, retrieved 2026-10-26)
- Completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT06045858, source copy `cardio:ctgov-nct06045858-2024-08-09`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06045858-2024-08-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
- Acronym: APIDP2
- Condition: Atrial Fibrillation
- Condition: Peritoneal Dialysis Complication
- Intervention (Drug): Anticoagulation Agents
- Lead sponsor: University Hospital, Caen
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: University Hospital, Caen (`cardio:org-university-hospital-caen`)

## Provenance

Content hash: 6db0eb2238728d53428b85ed7622732c857250b2c2f7a31993301bf7c90b79f6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
